Expertise in
12
conditions
Expertise in
12
conditions
601 Elmwood Ave Box 777, 
Rochester, NY 

Overview

Jeffrey Andolina is a Pediatric Hematologist Oncology provider in Rochester, New York. Dr. Andolina is highly rated in 12 conditions, according to our data. His top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Histiocytosis, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 38 peer reviewed articles and participating in 42 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

601 Elmwood Ave Box 777, Rochester, NY 14642

Additional Areas of Focus

Dr. Andolina has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


41 Clinical Trials

Neuroblastoma Biology Studies
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Haploidentical Donor Hematopoietic Stem Cell Transplantation
View 37 Less Clinical Trials
Similar Doctors
Expertise in
3
conditions
Pediatric Hematology Oncology
Expertise in
3
conditions
Pediatric Hematology Oncology
601 Elmwood Ave, Box 635, 
Rochester, NY 
 (2.3 miles away)
Languages Spoken:
English

Barbara Asselin is a Pediatric Hematologist Oncology provider in Rochester, New York. Dr. Asselin is highly rated in 3 conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, and L1 Syndrome.

Expertise in
11
conditions
Pediatric Hematology Oncology
Expertise in
11
conditions
Pediatric Hematology Oncology
601 Elmwood Ave, 
Rochester, NY 
 (2.3 miles away)
Languages Spoken:
English

Angela Girvin is a Pediatric Hematologist Oncology provider in Rochester, New York. Dr. Girvin is highly rated in 11 conditions, according to our data. Her top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Hepatoblastoma, and Bone Marrow Aspiration.

Expertise in
8
conditions
Pediatric Hematology Oncology
Expertise in
8
conditions
Pediatric Hematology Oncology

University Of Rochester

601 Elmwood Ave, 
Rochester, NY 
 (2.3 miles away)
Languages Spoken:
English

Craig Mullen is a Pediatric Hematologist Oncology provider in Rochester, New York. Dr. Mullen is highly rated in 8 conditions, according to our data. His top areas of expertise are Reticulohistiocytoma, Histiocytosis, Langerhans Cell Histiocytosis, Hepatoblastoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Andolina's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 23 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile